Compare MRT & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRT | PEPG |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | Turkey | United States |
| Employees | N/A | N/A |
| Industry | Rental/Leasing Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.2M | 207.1M |
| IPO Year | 2021 | 2022 |
| Metric | MRT | PEPG |
|---|---|---|
| Price | $1.95 | $3.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $3.58 | ★ $11.17 |
| AVG Volume (30 Days) | 46.0K | ★ 994.9K |
| Earning Date | 08-08-2018 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.61 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $72.36 | N/A |
| Revenue Next Year | $95.75 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.12 | $1.31 |
| 52 Week High | $2.75 | $7.80 |
| Indicator | MRT | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 64.77 | 62.20 |
| Support Level | $1.99 | $1.47 |
| Resistance Level | $2.29 | $3.14 |
| Average True Range (ATR) | 0.13 | 0.21 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 92.73 | 37.41 |
Marti Technologies Inc is Turkiye's urban mobility platform, helping to solve the country's transportation needs through tech-enabled services powered by a single mobility super app. The Group aims to offer tech-enabled urban transportation services to consumers across Turkiye through three service offerings: ride-hailing, delivery, and two-wheeled electric vehicle services. The Group's ride-hailing service matches consumers with car, motorcycle, and taxi drivers. The Group's delivery service provides same-hour package delivery by leveraging the Group's existing network of car and motorcycle drivers and consumer base.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.